ReNeuron

Olav Hellebo, CEO
Bridgend, UK
(LON: RENE)
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, ReNeuron has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia, and for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.
www.reneuron.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions